CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 38 enrolled
Drug / intervention
Tositumomab and Iodine I 131 Tositumomabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00933335
NCT00933335Phase 2Completed
CompareCT.gov

Fludarabine Monophosphate Followed by Iodine I 131 Tositumomab for Untreated Low-grade and Follicular Non-Hodgkin's Lymphoma

GlaxoSmithKline·interventional·Posted Jul 7, 2009·Updated Jan 18, 2017

In Brief

A Phase 2 clinical trial evaluating Tositumomab and Iodine I 131 Tositumomab for Lymphoma, Non-Hodgkin. Completed, enrolled 38 participants.

Detailed Summary

This is a single-arm, single institution, phase II study of fludarabine monophosphate followed by Iodine I 131 Tositumomab for patients with previously untreated, advanced-stage (stage III or IV) low-grade, transformed low-grade and follicular non-Hodgkin's lymphoma. The primary objective of the study will be to evaluate the safety of this treatment combination and the secondary endpoint will be to evaluate efficacy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Non-Hodgkin
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 7, 2009
Enrollment StartAug 1, 1998
Primary CompletionDec 1, 2009
Study CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 11.3 yearsPosted 17.0 years ago

Interventions

Tositumomab and Iodine I 131 Tositumomabbiological

Tositumomab and Iodine I 131 Tositumomab